Status:
ACTIVE_NOT_RECRUITING
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Patient-Centered Outcomes Research Institute
Hackensack Meridian Health
Conditions:
Multiple Myeloma
Hodgkin Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of addin...
Eligibility Criteria
Inclusion
- age 18 or older
- pathological diagnosis of MM, HD or NHL
- scheduled for high dose chemotherapy for auto-HSCT in the following month (30 days)
- not taking opioids regularly in the week prior to consent (one-time dosing of opioids for a painful procedure is allowed)
Exclusion
- absolute neutrophil count (ANC) of \<500/μl, platelet count of \<20,000/ μl or INR \>2.0
- acupuncture within two weeks prior to HiChemo (to avoid residual effects of acupuncture)
- unable to provide informed consent
Key Trial Info
Start Date :
June 30 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2026
Estimated Enrollment :
299 Patients enrolled
Trial Details
Trial ID
NCT04459416
Start Date
June 30 2020
End Date
June 1 2026
Last Update
October 20 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065
2
Fred Hutchinson Cancer Research Center
Seattle, Washington, United States, 98109
3
Seattle Cancel Care Alliance (Data Collection Only)
Seattle, Washington, United States, 98109